Donor Treg cells plus IL-2 for stubborn chronic GVHD
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had a stem cell transplant from a donor (allo-HSCT).
- You have moderate to severe chronic graft-versus-host disease (cGVHD) that does not get better with steroids or requires high doses of steroids.
- You are on a stable dose of prednisone (a steroid) for at least 4 weeks before the treatment starts.
- Your major organs (kidneys, heart, lungs, liver) are working well enough, and your blood counts are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests whether giving special immune cells (regulatory T cells) grown in a lab, along with a low dose of interleukin-2, can help people with chronic graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.